These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6105787)

  • 21. Roles of dopamine and its receptors in generation of choreic movements.
    Kanazawa I; Murata M; Kimura M
    Adv Neurol; 1993; 60():107-12. PubMed ID: 8093572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Some pharmacological aspects of neuroleptics (author's transl)].
    Niemegeers CJ
    Encephale; 1981; 7(3):215-24. PubMed ID: 6116591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New selective dopamine D-2 antagonists as antipsychotic agents. Pharmacological, chemical, structural and theoretical considerations.
    Högberg T; Rämsby S; Ogren SO; Norinder U
    Acta Pharm Suec; 1987; 24(6):289-328. PubMed ID: 2898864
    [No Abstract]   [Full Text] [Related]  

  • 24. [Correlation of dopamin- and GABA-ergic mechanisms in the depressive effect of neuroleptics on pedal self-stimulation of the ventral tegmentum of the mesencephalon].
    Talalaenko AN; Boreĭsha IK
    Farmakol Toksikol; 1983; 46(2):36-9. PubMed ID: 6133777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for drug actions on both pre- and postsynaptic catecholamine receptors in the CNS.
    Bunney BS; Aghajanian GK
    Psychopharmacol Bull; 1975 Oct; 11(4):8-10. PubMed ID: 724
    [No Abstract]   [Full Text] [Related]  

  • 26. [A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
    Matsubara R
    Hokkaido Igaku Zasshi; 1993 Jul; 68(4):570-82. PubMed ID: 7687976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrograde signaling at central synapses via endogenous cannabinoids.
    Kano M; Ohno-Shosaku T; Maejima T
    Mol Psychiatry; 2002; 7(3):234-5. PubMed ID: 11920149
    [No Abstract]   [Full Text] [Related]  

  • 28. [3H]Sulpiride, a ligand for neuroleptic receptors.
    Freedman SB; Poat JA; Woodruff GN
    Neuropharmacology; 1981 Dec; 20(12B):1323-6. PubMed ID: 6119644
    [No Abstract]   [Full Text] [Related]  

  • 29. [Molecular structures of anticonvulsants: molecular neurobiology of epilepsy].
    Böhme I; Lüddens H
    Pharm Unserer Zeit; 2007; 36(4):262-8. PubMed ID: 17623315
    [No Abstract]   [Full Text] [Related]  

  • 30. Animal models of tardive dyskinesia--a review.
    Kulkarni SK; Naidu PS
    Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological and biochemical evidence for an interaction between the benzodiazepine and GABA receptors.
    Guidotti A
    Adv Biochem Psychopharmacol; 1980; 21():271-5. PubMed ID: 6246742
    [No Abstract]   [Full Text] [Related]  

  • 32. Modulation of dopamine receptor binding by ascorbic acid.
    Madras BK; Chan B
    Adv Biochem Psychopharmacol; 1983; 37():275-87. PubMed ID: 6138950
    [No Abstract]   [Full Text] [Related]  

  • 33. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes.
    Singh AN; Barlas C; Singh S; Franks P; Mishra RK
    J Psychiatry Neurosci; 1996 Jan; 21(1):29-35. PubMed ID: 8580115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine receptor pharmacology.
    Seeman P; Van Tol HH
    Curr Opin Neurol Neurosurg; 1993 Aug; 6(4):602-8. PubMed ID: 8104554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic neuroleptic treatment and dopamine receptor regulation.
    Creese I; Snyder SH
    Adv Biochem Psychopharmacol; 1980; 24():89-94. PubMed ID: 6105809
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats.
    Jenner P; Kerwin R; Rupniak NM; Murugaiah K; Hall MD; Fleminger S; Marsden CD
    J Neural Transm Suppl; 1983; 18():205-12. PubMed ID: 6135741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of long-term neuroleptic administration on CNS receptors plasticity].
    Allikmets LKh; Zharkovskiĭ AM; Nurk AM; Vasar EE; Maĭmets MO
    Vestn Akad Med Nauk SSSR; 1984; (11):37-42. PubMed ID: 6152099
    [No Abstract]   [Full Text] [Related]  

  • 40. [Rationalizing the effect of antipsychotic agents].
    Sokoloff P
    Encephale; 1999 Nov; 25 Spec No 4():50-2. PubMed ID: 10609113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.